BCL11B is required for positive selection and survival of double-positive thymocytes

To study the role of BCL11B beyond the DN3 stage of T cell development, we used the “floxed” BCL11B mice (BCL11B^F/F) in which the exon 3, covering most of the BCL11B open reading frame (24), was flanked by LoxP sites (unpublished data). Removal of BCL11B was achieved by crossing the BCL11B^F/F mice with the CD4cre transgenic mice, expressing the Cre recombinase after β selection (25). Cre-mediated removal of BCL11B was confirmed by quantitative (q) RT-PCR, immunoblot, and flow cytometry analysis. BCL11B was removed in DP thymocytes, as well as in the small numbers of CD4 and CD8 SP thymocytes, but was still present in DN thymocytes (Fig. S1). The antibodies used for detection of BCL11B correspond to an epitope in exon 2, aa 26–44 (21, 22), outside of the removed exon.

Thymi of 5–6 wk old BCL11B^F/FCD4cre mice were reduced in size (Fig. 1), and thymic cellularity was reduced by 35%; however, DP thymocytes were present, indicating that they passed β-selection (Fig. 2, A and C). There was a major reduction in the percentage and absolute numbers of CD4 and CD8 SP thymocyte populations (Fig. 2, A and C), suggesting that their differentiation from DP to SP thymocytes was compromised. In addition, the small numbers of BCL11B-deficient CD4 and CD8 SP thymocytes have reduced levels of TCRβ (Fig. 2 B), indicating that they are immature.

The mesenteric lymph nodes and the spleens of BCL11B^F/FCD4cre mice, as well as of the BCL11B^F/FCD4cre/TCR transgenic mice (see bellow), were considerably enlarged (Fig. 1 and Fig. S2), and their total cellularity was increased (Table I and Table II), whereas the increase in the cervical lymph nodes and total cellularity was more modest (Table I). The percentages and absolute numbers of CD4⁺ and CD8⁺ T lymphocytes were reduced in lymph nodes and spleen (Fig. 3, A and B; Table I and Table II). TCRβ levels were reduced in the small number of BCL11B-deficient peripheral T lymphocytes (Fig. 3 C), suggesting that they are immature. In addition, there was a major reduction in the percentage of naive CD62L^highCD44^low CD4⁺ and CD8⁺ T lymphocyte populations, whereas the CD44^high populations, comprising activated and memory-like T cells, were increased (Fig. 3 D), results which suggest a homeostatic deregulation in CD4⁺ and CD8⁺ T lymphocyte populations, which is often observed in lymphopenic mice (26). The lymph nodes and spleens of BCL11B^F/FCD4cre mice presented a marked increase in percentage and absolute numbers of B220⁺ lymphocytes (Table I and Table II). In addition to the increased numbers of B220⁺ lymphocytes, the spleens of BCL11B^F/FCD4cre mice presented increased numbers of macrophages, dendritic cells, NK, megakaryocytes and TCRγδ populations (Table II), suggesting alterations in homeostasis. This was not the case in a TCRα^−/− background (Table S1), demonstrating that the increase in the numbers of these populations is dependent on the presence of the few BCL11B-deficient T cells present in the periphery.

The defects in the BCL11B^F/FCD4cre T lymphocytes are likely initiated by the perturbations at the DP stage at T cell development when BCL11B is removed. To obtain further insight into the mechanism underlying the altered thymic development, we first investigated whether the reduction in the numbers of SP thymocytes was caused by a defect in positive selection. During positive selection, CD69 expression is induced (4) and CD5 (5) and TCRβ (1) are up-regulated. Our results show that BCL11B^F/FCD4cre mice have a marked reduction in the CD69⁺TCRβ^high DP thymocyte population (Fig. 4 A), indicating that they are unable to pass positive selection. We also evaluated the percentage of HSA^lowTCRβ^high thymocyte population, which contains DP thymocytes that passed positive selection, as well as mature SP thymocytes, and found that it was lower in the BCL11B^F/FCD4cre mice (Fig. 4 B). In addition, a detailed analysis of the surface levels of CD69, TCRβ, and CD5 showed a profound decrease in the populations expressing high levels of CD69, CD5, and TCRβ (Fig. 4 C), further demonstrating that positive selection was altered.

Germline BCL11B-deficient mice have a block in β-selection caused by unsuccessful TCRβ rearrangements (23). Therefore, the reduction in the number of postselected DP thymocytes in BCL11B^F/FCD4cre mice may be caused by the observation that these DP thymocytes do not appropriately rearrange TCRα. Analysis of TCRα rearrangements demonstrated that both early and late rearrangements proceeded similarly in BCL11B-deficient and control DP thymocytes (Fig. 4 D), indicating that the defect in positive selection is unlikely to be caused by impaired TCRα rearrangements. Thus, BCL11B does not control rearrangements at the TCRα locus, although it was previously suggested to be implicated in the control of rearrangements at the TCRβ locus (23).

To further facilitate the examination of positive selection, we analyzed BCL11B^F/FCD4cre thymocytes expressing transgenic TCRs that recognize specific antigens presented in the context of MHC class I or II. Positive selection of CD4 lineage was investigated with the OT-2 TCR transgenic mice that express a TCR composed of Vα2/Vβ5 chains, recognizing the OVA peptide 323–339 in the context of MHC class II I-A^b (27). The analysis indicated a severe decrease in the percentage of CD4 SP thymocytes (Fig. 5 A, a), as well as peripheral CD4⁺ T lymphocytes (Fig. 5 A, f), both in percentage and absolute numbers (Fig. 5 B). The same reduction was observed when gating on the TCRα2β5^high population (Fig. 5 A, b). Moreover, both TCRβ5^highCD69^high DP and TCRβ5^highHSA^low thymocyte populations remained low (Fig. 5 A, c and d), demonstrating that positive selection of CD4 lineage was impaired. In support of this conclusion, the number of TCRα2β5^high DP thymocytes up-regulating CD5 levels was severely reduced (Fig. 5 A, e). Collectively, these results demonstrate that antigen-specific positive selection of CD4 lineage was majorly altered in BCL11B^F/FCD4cre mice.

To evaluate positive selection of CD8 lineage, we used the H-Y TCR transgenic mice, which express a TCR that recognizes an antigen derived from the male-specific Smcy protein in the context of H-2D^b MHC class I and support positive selection of the CD8 lineage in female mice (28). H-YTCR/BCL11B^F/FCD4cre females had reduced percentages and absolute numbers of CD8 SP thymocytes (Fig. 5 C, a, and D). Similar results were obtained when gating on the T3.70^high (H-YTCR^high) population (Fig. 5, C [b] and D). The HY-TCR^high/HSA^low and H-YTCR ^highCD69⁺ populations continued to be low, and the surface level of CD5 was significantly decreased (Fig. 5 C, c–e). Supporting the observation that positive selection was impaired, the peripheral CD8⁺ T lymphocyte population was diminished (Fig. 5 C, f). Collectively, these results demonstrate that, in the absence of BCL11B, positive selection of the CD8 lineage was impaired, and therefore BCL11B is essential for positive selection of both CD4 and CD8 lineages. In addition, these results suggest that the defect in positive selection is not caused by the TCR itself. A detailed analysis of the cellularity in TCR transgenic and nontransgenic BCL11B^F/FCD4cre mice indicated a more severe decrease in the number of CD4 than in the number of CD8 SP thymocytes in the absence of BCL11B (Fig. 5, B and D, and Fig. 2 C), suggesting that selection of the CD4 lineage was more severely altered compared with the CD8 lineage.

Finally, provision of transgenic H-Y or OT-2 TCRs did not restore the absolute numbers of DP thymocytes (Figs. 5, B and D), suggesting that survival of BCL11B-deficient DP thymocytes (see below) remains perturbed even in conditions that favor positive selection to CD4 or CD8 lineages.

Signaling events downstream of the TCR play a critical role in positive selection. To further determine the cause of the defect in positive selection of BCL11B-deficient DP thymocytes, we examined their responses to TCR stimulation. Specifically, we assessed the Ras–MEK–ERK pathway and calcium mobilization, as these TCR responses play an essential role in positive selection (29–31). Our results demonstrated that ERK phosphorylation was altered both in total DP (Fig. 6 A), as well as in the presignaled CD69⁻ DP thymocytes (Fig. 6 B).

Similarly, calcium mobilization in response to TCR activation was attenuated in presignaled CD69⁻ DP thymocytes (Fig. 6 C), and this was not caused by reduced levels of inositol 1,4,5-triphosphate receptor (Fig. S3). In DP thymocytes, calcium mobilization in response to TCR signaling results in nuclear translocation of the transcription factor NFAT4 (12). Indeed, our results showed reduced nuclear translocation of NFAT4 in the BCL11B-deficient DP thymocytes (Fig. 6 D), supporting the observation that calcium flux was altered.

To further define the defect in the TCR signaling in BCL11B-deficient DP thymocytes, we investigated proximal events of TCR signaling, including phosphorylation of ZAP70 kinase and of the adaptor molecule SLP76. Our results demonstrated that both ZAP70 and SLP76 phosphorylation was altered in the absence of BCL11B (Fig. 6 E), suggesting that early events upstream of calcium flux and ERK phosphorylation are perturbed in BCL11B-deficient DP thymocytes. Together, these results suggest that BCL11B controls proximal events of TCR signaling and/or a pathway that regulates TCR signaling.

Although the defect in positive selection can explain the reduced numbers of CD4 and CD8 SP thymocytes, it does not explain the reduction in the absolute number of DP thymocytes in BCL11B^F/FCD4cre mice (Fig. 2 C). This reduction suggests that BCL11B-deficient DP thymocytes die more compared with wild type. Our hypothesis was that BCL11B-deficient DP thymocytes have an intrinsic defect in survival, as opposed to dying through negative selection, because of their overall reduced capacity to signal through TCR (see above), and also because of the observation that removal of BCL11B in DN3 thymocytes and in cell lines was demonstrated to predispose them to apoptosis (23, 32). To eliminate the possibility that the reduction in DP thymocytes is caused by negative selection, we conducted the following experiments. (a) We crossed the BCL11B^F/FCD4cre mice with TCRα^−/− mice in which DP thymocytes fail to undergo positive or negative selection and die by neglect because of the lack of TCR signaling. The results show that total and DP thymocyte absolute numbers still remained reduced in BCL11B^F/FCD4cre/TCRα^−/− compared with TCRα^−/− mice (Fig. 7 A), demonstrating that BCL11B-deficient DP thymocytes die more even in the absence of TCR signaling. (b) Because of the observation that the numbers of DP thymocytes were severely reduced in conditions of provision of transgenic TCRs in BCL11B^F/FCD4cre mice (Fig. 5, B and D), to further eliminate the possibility that TCR signaling itself induces active cell death in TCR transgenic BCL11B^F/FCD4cre mice, we conducted reconstitution experiments with OT2/BCL11B^F/FCD4cre bone marrow cells in nonselective (I-A^d) versus selective (I-A^b) recipients. Our results demonstrate that even in a nonselective (I-A^d) background the absolute numbers of OT2/BCL11B^F/FCD4cre DP thymocytes were still reduced compared with OT2/BCL11B^F/F DP thymocytes (Table S2), again demonstrating that even in the absence of TCR signaling they die more. On a selective background (I-A^b), formation of CD4 SP thymocytes in mice reconstituted with OT2/BCL11B^F/FCD4cre bone marrow remained impaired (Table S2), demonstrating that the defect in positive selection is cell intrinsic. Similarly, the numbers of reconstituted OT2/BCL11B^F/FCD4cre DP thymocytes remained reduced compared with OT2/BCL11B^F/F DP thymocytes (Table S2), despite the observation that the reconstitutions were initiated with the same numbers of bone marrow cells. One possible explanation for the enhanced cell death that we observed in BCL11B^F/FCD4cre TCR transgenic mice compared with polyclonal TCR background may be related to the observation that the expression of TCR transgenes is initiated before cells become DP (33). Although in wild-type mice this may favor an earlier selection compared with a polyclonal background, it is possible that in BCL11B^F/FCD4cre mice, the cells that express TCR, but fail to be selected, die. This is plausible because removal of the floxed allele in CD4-Cre model is initiated past DN3 stage and continues on during the DP stage (25).

We also evaluated the survival of BCL11B-deficient DP thymocytes in vitro and the results showed that it was lower compared with wild-type control (Fig. 7 B), indicating that BCL11B-deficient DP thymocytes are more sensitive to spontaneous apoptosis. Similarly, DP thymocytes of BCL11B^F/FCD4cre/TCRα⁻ mice also died more in vitro (Fig. 7 C), supporting the hypothesis that their enhanced apoptosis is the result of death by neglect or an intrinsic predisposition to cell death. To further support the idea that BCL11B promotes survival of T lymphocytes, we used a Jurkat cell line model that overexpresses BCL11B, generated through retroviral transduction (22). Our results demonstrate that overexpression of BCL11B conferred increased protection to apoptosis to Jurkat cells (Fig. S4), suggesting that BCL11B supports survival of immature and transformed T cells.

To investigate the mechanism by which BCL11B^F/FCD4cre DP thymocytes die, we first evaluated the levels of cleaved caspase 3, which is downstream of both intrinsic and extrinsic apoptotic pathways. Cleaved caspase 3 levels were elevated in BCL11B-deficient DP thymocytes (Fig. 7 D), demonstrating the implication of this effector caspase. The reduced survival of BCL11B-deficient DP thymocytes could be caused by a decrease in the levels of BCLXL, which plays a prominent role in DP thymocyte survival (34). However, we found only a very modest decrease of BCLXL protein levels (Fig. 7 D). As survival/apoptosis is determined by the balance between prosurvival versus proapoptotic factors, we further evaluated the protein levels of several proapoptotic factors, and found only modest increases in Bim, Puma, Bok, and Bad levels (Fig. 7 D). Overall, the balance between proapoptotic/prosurvival factors was inclined toward apoptosis. To further clarify whether the imbalance in proapoptotic/prosurvival factors is the cause of enhanced apoptosis, we provided transgenic BCL2, as BCL2 and BCLXL were demonstrated to be equally potent in inhibiting thymocyte death (34–37). In vitro survival of BCL11B-deficient DP thymocytes was improved by provision of BCL2 transgene (Fig. 7 E), suggesting that BCL2 family proteins play a role in survival mediated by BCL11B. The levels of cleaved caspase 3 still remained slightly elevated (Fig. 7 F). However, the cellularity of the transgenic BCL2/BCL11B-deficient thymi, including the absolute numbers of DP thymocytes, remained severely reduced (Fig. 7 G), indicating that the survival of BCL11B-deficient DP thymocytes was not restored in vivo. These results suggest that although BCL2 family members play a role in the survival defect of BCL11B-deficient DP thymocytes, other mechanisms are also likely to be involved. Finally, provision of BCL2 did not restore the CD4 and CD8 SP thymocyte numbers or positive selection (Fig. 7 G and Fig. S5).

As BCL11B is a transcription factor, we reasoned that the defects of BCL11B-deficient DP thymocytes are caused by changes in gene expression. We conducted a gene expression profiling in BCL11B-deficient DP thymocytes versus wild-type control (unpublished data) and focused our analysis on genes relevant for positive selection, signaling, and survival/apoptosis. Expression of candidate genes was confirmed by qRT-PCR (Fig. 8 A). To eliminate the possibility that the differences in the mRNA levels are a consequence of the absence of postselected DP thymocytes in BCL11B^F/FCD4cre mice, for genes with relevance for TCR signaling and positive selection, we also tested the mRNA levels in TCRα^−/− DP thymocytes, which predominantly consist of presignaled DP thymocytes (Fig. 8 A). mRNAs for three molecules previously linked to positive selection were found to be deregulated in BCL11B-deficient DP thymocytes, i.e., programmed cell death 1 (PD-1), p55 γ adaptor subunit of PI 3-kinase (Pik3r3), and CD5 (Fig. 8 A). PD-1, which is a member of B7/CD28 costimulatory receptors, previously demonstrated to alter positive selection when transgenically overexpressed in DP thymocytes (38). Interestingly, PD-1 mRNA and protein levels were up-regulated in BCL11B-deficient DP thymocytes (Fig. 8, A and B), thus suggesting that this molecule can be implicated in the mechanisms that alter signaling and positive selection of BCL11B-deficient DP thymocytes.

Another candidate gene associated with TCR signaling was the γ adaptor subunit (Pik3r3), which is an enzyme previously shown to be implicated in positive selection downstream of TCR engagement and upstream of calcium mobilization (39).

In addition, CD5 mRNA levels were reduced in BCL11B-deficient DP thymocytes (Fig. 8 A), and this was not just a consequence of the failure to pass positive selection, as the surface and intracellular levels of CD5 were also reduced in BCL11B-deficient presignaled CD69⁻ DP thymocytes (Fig. 8 C and not depicted). As expected, CD5 remained reduced in postselected CD69⁺ DP thymocytes, as well as in CD4 and CD8 SP thymocytes (Fig. 8 C). These results collectively demonstrate that BCL11B-deficient DP thymocytes have multiple defects in expression of genes associated with positive selection, consistent with the functional defects of BCL11B-deficient DP thymocytes.

In regard to survival/apoptosis, mRNA levels of BCLXL and BCL2 were modestly down-regulated, suggesting that they may be candidate target genes, whereas the mRNA levels for the proapoptotic factors deregulated at protein level (Fig. 7 D) were found unchanged (not depicted), suggesting that these genes are not candidate targets. In addition, the gene encoding pleckstrin homology-like domain, family A, member 1 (Phlda1), also known as T cell death associated gene 51 (Tdag51), which was previously found to induce cell death in different cellular systems (40), was highly expressed in BCL11B-deficient thymocytes (Fig. 8 A), suggesting that it may play a role in enhanced apoptosis.

In addition to genes associated with positive selection and survival, two genes encoding membrane-associated proteins, CD160 and Ly6c, which are normally not expressed in DP thymocytes, were up-regulated BCL11B-deficient DP thymocytes (Fig. 8 A). CD160 (BY55) is an Ig-like receptor expressed in NK, NKT, and cytotoxic T cells, and has broad specificity binding for classical and nonclassical MHC class I molecules (41–43). Ly6c is a GPI-anchored cell surface protein known to mediate inhibitory signals on effector CD4⁺ T cells (44–46). These results suggest that potentially inappropriate signals may be initiated in BCL11B-deficient DP thymocytes, which may interfere with TCR signaling and the main program at this stage of T cell development.

In this study, we investigated how selective removal of BCL11B at the DP stage of T cell development impacts positive selection and survival of DP thymocytes. Positive selection of both CD4 and CD8 lineages was compromised in BCL11B^F/FCD4cre mice. However, this was not a consequence of a failure to rearrange TCRα, as rearrangements proceeded normally in the absence of BCL11B. The induction of CD69 expression and up-regulation of CD5 and TCRβ, which are hallmarks of proficient progression through positive selection (1), were altered in BCL11B-deficient DP thymocytes. The reduction in the formation and implicit selection of the CD8 lineage was less severe than that of the CD4 lineage. Interestingly, these results are similar to the phenotypes described in mice with defects in genes encoding TCR signaling components, such as those of the Ras–MEK–ERK pathway, including MEK1 (29), Ras (47), and ERK1 and ERK2 (31). Nevertheless, provision of a transgenic TCR that favors positive selection of the CD8 lineage did not restore the selection and formation of CD8 lineage, strongly suggesting that they are altered in the absence of BCL11B. Positive selection and formation of the CD4 lineage was severely compromised, and provision of a transgenic TCR that favors selection of the CD4 lineage did not restore it either. Therefore, these studies suggest that the defect in positive selection is not caused by the TCR itself, but likely by molecules implicated in TCR signaling and/or a pathway that affects TCR signaling. This idea is also supported by previous observations, which demonstrated that provision of TCRαβ in the germline BCL11B-deficient mice only partially rescued the developmental arrest at the β-selection (48), altogether suggesting that BCL11B may directly or indirectly control signaling components downstream of the TCR and/or a pathway that impacts TCR signaling. In support of this hypothesis, our results demonstrate that signaling through the two major pathways, which are activated through TCR during positive selection, Ras–MEK–ERK pathway, and Ca²⁺ flux (1, 29–31, 47, 49), is altered in BCL11B-deficient DP thymocytes. Moreover, phosphorylation of ZAP70 and SLP76 was also altered in BCL11B-deficient DP thymocytes, suggesting a defect in proximal TCR signaling and/or in a pathway that proximally impacts TCR signaling. There are several transcription factors with roles in positive selection known to act distally in TCR signaling, downstream of ERK or calcium signaling activation. Such examples include SAP1, which is a direct target of ERK phosphorylation (9), its target EGR1 (10), as well as EGR1's target Id3 (11), and NFAT4, which is a target for calcium signaling (12). Different from these transcription factors, BCL11B seems to have a very unique position, controlling proximal events of TCR signaling, and/or a pathway that impacts TCR signaling. How does BCL11B specifically direct transcriptional events required for successful positive selection of DP-positive thymocytes? We identified several “candidate” genes previously implicated in positive selection and signaling with altered mRNA levels in BCL11B-deficient DP thymocytes. One such candidate up-regulated in BCL11B-deficient DP thymocytes, both at mRNA and protein level, is PD-1, which is a member B7/CD28 costimulatory receptors (50–52). PD-1 was shown to diminish TCR signaling and ERK phosphorylation, and to alter positive selection (38) by diminishing Zap70 activity by recruitment of the inhibitory SHP-1 and -2 phosphatases through immunoreceptor-tyrosine inhibition motif (38, 53). Indeed, not only calcium flux and ERK phosphorylation were defective in BCL11B-deficient DP thymocytes but also phosphorylation of ZAP70, which is an indication of its altered function. Thus, the high levels of PD-1 in BCL11B-deficient DP thymocytes may account for altered TCR signaling, and implicitly defective positive selection. Another candidate gene found to be down-regulated in BCL11B-deficient DP thymocytes is Pik3r3, which is an understudied adaptor subunit of PI3-kinase. Previous findings implicated PI3-kinase in positive selection through the catalytic subunit p110α (39). However, it was reported that despite a major block in B lymphocyte development, no disruption of positive selection was observed in the absence of the α (Pik3r1) and β (Pik3r2) adaptor subunits (54, 55). Interestingly, in thymocytes of these mice, the expression of the third adaptor subunit, γ or Pik3r3, was found to be up-regulated. Therefore, it is tempting to speculate that the adaptor subunit γ (Pik3r3), identified by us as a candidate gene down-regulated in BCL11B-deficient DP thymocytes, may be the adaptor subunit of PI 3-kinase responsible for positive selection of DP thymocytes. Thus, the lower Pik3r3 levels in BCL11B-deficient DP thymocytes may participate in the altered calcium flux. In addition to the two molecules implicated in TCR signaling, CD5 was found to be reduced both at mRNA and protein levels, indicating that positive selection is compromised at multiple levels and in a complex manner. To this end, it is also possible that the defect in positive selection in BCL11B-deficient DP thymocytes is not only the result of direct alterations in TCR signaling. Rather, other surface molecules may provide signals that perturb TCR signaling, compromising positive selection. In this regard, we found increased mRNA levels for two membrane-associated proteins, CD160 and Ly6c, which are normally not expressed in DP thymocytes, but which are able to initiate signaling in NK, CD8⁺, and CD4⁺ T lymphocytes (41, 45, 46). Such signals initiated in DP thymocytes may interfere with the normal TCR signaling and the program of DP thymocytes.

BCL11B-deficient DP thymocytes also presented enhanced apoptosis. Interestingly, other previously reported deficiencies in positive selection, associated with defects in CD3δ (56), Lck (57, 58, 59), MEK1 (29), Ras (47), Raf-1 (60), and ERK1 and ERK2 (31), were not accompanied by a major impairment in survival, which suggests that the reduced survival of BCL11B-deficient DP thymocytes may be independent of the defect in positive selection. This hypothesis is supported by the observation that BCL11B-deficient DP thymocytes continued to exhibit enhanced death even in the absence of TCR signaling, as demonstrated by the experiments with TCRα^−/− mice. Interestingly, BCL11B-deficient DP thymocytes still survive long enough to rearrange TCRα. This phenotype is different from the RORγ deficiency, in which altered survival of DP thymocytes impairs TCRα rearrangements (61, 62). Of interest, BCL11B-deficient DN3 thymocytes were also more susceptible to apoptosis (23). Thus, it is possible that BCL11B may control thymocyte survival both at the DP and at earlier stages of T cell development. We observed enhanced levels of cleaved caspase 3 and an imbalanced proapoptotic/prosurvival factors in BCL11B-deficient DP thymocytes, and extensively evaluated the mRNA levels of multiple proapoptotic and prosurvival factors, including BCLXL, BCL2, Bad, Bok, Puma, and Bim. Except for the modest down-regulation of BCLXL and BCL2, we failed to see any differences in the mRNA levels of the aforementioned proapoptotic factors, suggesting that these genes are not candidate targets. The observation that transgenic BCL2 failed to rescue cellularity in vivo strongly suggests the implication of other pathways in the enhanced apoptosis of BCL11B-deficient DP thymocytes. In this regard, the mRNA for Phlda1/Tdag51 was found to be up-regulated in BCL11B-deficient DP thymocytes. Interestingly, Phlda1/Tdag51 was found to act both on death receptor-dependent and -independent pathways (40, 63), raising the possibility that this factor may be implicated in the enhanced apoptosis of BCL11B-deficient DP thymocytes.

Overall, the results presented here demonstrate a complex and unique role of the BCL11B transcription factor in the control of both positive selection and survival of DP thymocytes.

Mice carrying the floxed BCL11B alleles (BCL11B^F/F) were generated in 129S3 background and will be described elsewhere (unpublished data). BCL11B^F/F mice were backcrossed on C57BL/6 background for 5 generations using the “Speed Congenics” Technology, provided by The Jackson Laboratory, which allowed us to reach a 98% C57BL/6 background. BCL11B^F/F mice were crossed with C57BL/6 CD4Cre transgenic mice (line 4196; Taconic) (25) to generate conditional BCL11B^F/FCD4cre mice. To obtain H-Y TCR/- and OT-2 TCR/BCL11B^F/FCD4cre transgenic mice, were crossed with H-Y TCR (28) (Taconic) or OT-2 TCR mice (27) (The Jackson Laboratory). To obtain BCL2/BCL11B^F/FCD4cre transgenic mice, we crossed with BCL2 transgenic mice (34) (A. Singer, National Cancer Institute, Bethesda, MD). TCRα^−/− mice were purchased from The Jackson Laboratory. Experiments were conducted with 5–6 wk old mice, unless specified. Mice were kept under specific pathogen–free conditions in the animal care facility of Albany Medical College, and all animal procedures were approved by the Institutional Animal Care and Use Committee.

Primary cells were maintained in RPMI 1640. DP cells were enriched using anti-CD8 magnetic beads (Miltenyi Biotec), resulting in ∼95% DP thymocytes. The following antibodies were used for surface staining: anti-CD4 (clones RMA4-5 and GK1.5), -CD8 (clone 53–6.7), -TCRβ (clone H57-597), -TCRα2 (clone B20.1), -HYTCR (clone T3.70), -HSA (clone M1/69), -CD69 (clone H1.2F3), -CD5 (clone 53–7.3), -CD3 (clone 145-2C11), -TCRγδ (clone GL3), -B220 (clone RA3-6B2), -F4/80 (clone BM8), -CD11c (clone N418), -CD49b (clone DX5), -CD41 (clone MW Reg30; eBioscience), and -TCRβ5 antibodies (clone MR9-4; BD Biosciences). Intranuclear staining of BCL11B with the previously described anti-BCL11B antibodies (22) was conducted after staining for surface CD4 and CD8, followed by fixation and permeabilization with 1% Triton X-100. Determination of apoptosis in fresh or 16-h–cultured thymocytes was conducted by staining with AnnexinV (BD Biosciences) and 7-AAD (eBioscience) after surface staining for CD4 and CD8. Flow cytometry analysis was conducted on a FACSCanto instrument (BD Biosciences). Sorting of thymocytes was performed on a FACSAria instrument. Flow cytometry data was analyzed using FlowJo software (Tree Star, Inc).

For evaluation of gene expression, DP thymocytes were either sorted or purified by selection on anti-CD8 magnetic beads. qRT-PCR was conducted as previously described (22). The primers for q-PCR were chosen so as to extend products under 200 bp with no formation of primer dimers. The relative abundance of each message was normalized to actin and calculated as: 2^{−(Ct gene−Ct actin)}, where Ct represents the threshold cycle for each transcript. Sequence of the primers is available upon request.

Differences between various BCL11B^F/FCD4cre and control mice were analyzed by the two-tailed Student t test and expressed as the mean ± the SD. P ≤ 0.05 was considered significant for all analyses.

Fig. S1 shows selective removal of BCL11B starting with DP thymocytes. Fig. S2 shows that BCL11B^F/FCD4cre/OT2 and BCL11B^F/FCD4cre/HYTCR mice present enlarged spleens and mesenteric lymph nodes. Fig. S3 shows that inositol 1,4,5-triphosphate receptor expression is not affected in BCL11B-deficient DP thymocytes. Fig. S4 shows that BCL11B-overexpressing cells are more resistant to dexamethasone-induced cell death. Fig. S5 shows that provision of BCL2 does not restore positive selection of BCL11B^F/FCD4cre DP thymocytes and CD4 and CD8 SP thymocyte populations. Table S1 shows splenic Cellularity of BCL11B^F/FCD4Cre/TCRα^−/− mice. Table S2 shows the absolute number of thymocytes in mice reconstituted with bone marrow from TCR OT2 transgenics. A Supplemental materials and methods is available, describing in detail the experimental procedures for TCRα rearrangements, Western blot analysis, and intracellular calcium flux determination.

We greatly acknowledge Drs. Leszek Ignatowicz (Medical College of Georgia), Jonathan Harton, Jim Drake, Michelle Lennartz, Kevin Pumiglia, and Karen Duus, and all members of Avram laboratory (Albany Medical College) for valuable suggestions. We thank Dr. Mark Preissler (AMC) for advice with calcium flux, and Dr. Al Singer (NCI) for the BCL2 transgenic mice. We thank Dr. Douglas Cohn and Ms. Betsy Bashaw for care of the mice, and Ms. Debbie Moran for secretarial assistance. We acknowledge the contribution of the Albany Medical College flow cytometry facility, and thank Drs. Sridar Chittur and Scott Tenenbaum (Center for Functional Genomics, State University of New York at Albany) for the help with the microarray analysis.

This work was supported by K01 AR-02194 (National Institute of Arthritis and Musculoskeletal and Skin Diseases) and RSG-04-01-MGO (American Cancer Society) grants (to D. Avram) and training grant National Institutes of Health T32-HL-07194 (to D.I. Albu).

The authors have no conflicting financial interests.